贝伐单抗
免疫疗法
医学
癌症研究
肿瘤微环境
免疫抑制
癌症免疫疗法
癌症
血管内皮生长因子
免疫系统
血管生成
PD-L1
免疫学
血管内皮生长因子受体
内科学
化疗
作者
Daniel S. Chen,Herbert I. Hurwitz
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2018-07-01
卷期号:24 (4): 193-204
被引量:140
标识
DOI:10.1097/ppo.0000000000000327
摘要
Abstract Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway have demonstrated durable clinical benefit in some patients. However, CIT combinations may create a more favorable environment in which to maximize the potential of the immune system to eliminate cancer. Here we describe 3 key mechanisms related to vascular endothelial growth factor (VEGF)–mediated immunosuppression: inhibition of dendritic cell maturation, reduction of T-cell tumor infiltration, and promotion of inhibitory cells in the tumor microenvironment; supporting data are also described. In addition, we discuss immunomodulatory properties observed within tumors following bevacizumab treatment. Combining anti–PD-L1 and anti-VEGF therapies has shown synergy and positive outcomes in phases I to III studies, particularly in settings where high VEGF levels are known to play an important role in tumor growth. We also review data from key studies supporting combination of bevacizumab and CIT, with a focus on PD-L1/programmed death 1 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI